FY2022 EPS Estimates for BioSig Technologies, Inc. Raised by Taglich Brothers (NASDAQ:BSGM)

BioSig Technologies, Inc. (NASDAQ:BSGMGet Rating) – Equities researchers at Taglich Brothers lifted their FY2022 EPS estimates for BioSig Technologies in a research note issued to investors on Monday, November 21st. Taglich Brothers analyst J. Nobile now anticipates that the company will post earnings of ($0.59) per share for the year, up from their prior forecast of ($0.60). Taglich Brothers has a “Speculative Buy” rating on the stock. The consensus estimate for BioSig Technologies’ current full-year earnings is ($0.62) per share. Taglich Brothers also issued estimates for BioSig Technologies’ Q4 2022 earnings at ($0.11) EPS, Q1 2023 earnings at ($0.10) EPS, Q2 2023 earnings at ($0.09) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.07) EPS and FY2023 earnings at ($0.34) EPS.

Separately, Noble Financial reduced their price target on shares of BioSig Technologies to $2.00 in a research report on Thursday, November 17th.

BioSig Technologies Stock Performance

Shares of NASDAQ:BSGM opened at $0.38 on Thursday. The company’s fifty day moving average is $0.56 and its 200-day moving average is $0.75. BioSig Technologies has a 52 week low of $0.25 and a 52 week high of $3.12.

Institutional Trading of BioSig Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of BioSig Technologies by 6.7% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 345,807 shares of the company’s stock valued at $228,000 after buying an additional 21,618 shares during the last quarter. Commonwealth Equity Services LLC increased its position in BioSig Technologies by 24.2% during the 1st quarter. Commonwealth Equity Services LLC now owns 125,705 shares of the company’s stock worth $144,000 after buying an additional 24,500 shares during the period. Warberg Asset Management LLC bought a new position in BioSig Technologies during the 2nd quarter worth $43,000. Advisor Group Holdings Inc. increased its position in BioSig Technologies by 394.9% during the 1st quarter. Advisor Group Holdings Inc. now owns 85,859 shares of the company’s stock worth $99,000 after buying an additional 68,509 shares during the period. Finally, Truist Financial Corp bought a new position in BioSig Technologies during the 3rd quarter worth $114,000. 9.46% of the stock is owned by institutional investors.

BioSig Technologies Company Profile

(Get Rating)

BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.

Recommended Stories

Earnings History and Estimates for BioSig Technologies (NASDAQ:BSGM)

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.